やるじゃん、Coridon

Allied Healthcare Group（AHZ）が発表したところによると、AHZが筆頭株主となっている Coridon Pty Ltd が…、

「開発を進めているHSV2ワクチンが高い効果を示した」

ということのようです！



Coridon Pty Ltd は、オーストラリアのバイオ企業で、「IAN FRAZIER博士を中心にHSV-2をターゲットにしたワクチンの開発を進めている」ことは、以前にもこのブログで取り上げておりました（詳しくは、HSV 研究・治験21！　（6 & 7））。

どうやら、今回ご紹介する記事は、そのワクチンの経過報告ということなのでしょうね…。

現段階では、また動物実験の段階なのですが…、

• 以前行なったアメリカ ワシントン大学との共同研究では、90‐100％ウイルスの感染を防ぐことができた
• 今回 Coridon が行なった動物実験では、100％感染を予防することができた

という結果を得たようで、

今後が非常に楽しみな新薬候補の一つ

になるかと思います！


以下の記事を見る限り、

• どのような技術を使ってワクチンの開発を行なっているのかは明らかにされていない
• 感染予防だけでなく、「Theraputic（治療）」も薬品開発の視野に入っていると思われるが、その効果については述べられていない

ので、ちょっと今ひとつわからないところが多いのですが、まずは結果オーライというところでしょうか…（ちょっと日本語の使い方がオカシイような肝しますが…笑）

お時間がある時にでも、以下の記事を読んでみてください。



Allied Healthcare Group reports on Coridon testing against Herpes

http://www.proactiveinvestors.com.au/companies/news/20571/allied-healthcare-group-reports-on-coridon-testing-against-herpes-simplex-virus-2-using-dna-vaccine-20571.html

Allied Healthcare Group (ASX: AHZ) has reported that DNA vaccine development company Coridon Pty Ltd has successfully completed pre-clinical efficacy testing of its prototype Herpes Simplex Virus 2 (HSV-2) vaccine, with strong results.

Allied was spun out of miner, Fortescue Metals Group (ASX: FMG).*

Allied is a major shareholder in Coridon, and listed on the ASX in July 2011. In 2011, Allied earned revenues of $7 million.

Coridon will now progress the program into clinical studies.

Coridon was founded in 2000 by the globally renowned founder inventor Professor Ian Frazer as a private unlisted company, to develop and commercialise patented technology for improving immune responses to DNA vaccines licensed by UniQuest Pty Ltd and developed at the University of Queensland.

Coridon tested a number of different formulations of Coridon’s prototype vaccine. These proved 100% effective at protecting animals against HSV-2 infection, confirming an earlier study with the University of Washington which also demonstrated 90-100% protection against infection.

These results were presented at the 5th Vaccine and ISV Annual Global Congress in Seattle last week.

Lee Rodne, MD of Allied Healthcare Group said the data "provides fantastic validation to the Coridon platform which could be applied to a number of infectious diseases. We are excited about the path forward for the program as it moves toward clinical studies.”*

“The results of our herpes vaccine mark the beginning of an exciting period," Professor Ian Frazer, Chairman of Coridon said today.

"Over the next 12 months, we expect pivotal data showing that our HSV vaccine, which incorporates Coridon optimisation technology, produces similar immune responses in the clinic to those seen in the animal trials.”

Coridon is developing DNA vaccines for the prevention and treatment for a range of infectious diseases and cancers in humans, utilising the company’s patented technology. Coridon’s DNA vaccine technologies differ from conventional vaccines in that they offer both preventative and therapeutic value.

The company will now look to progress the program into clinical studies.

Coridon has now secured additional funding from major investor Allied Healthcare Group and plans to commence manufacturing and undertake formal pre-clinical safety studies before testing the vaccine in a Phase I clinical study.

In September, Allied secured a $5 million equity funding including funding from The Metal Group, an entity controlled by Fortescue's Andrew Forrest and substantial shareholder.